1. Introduction {#sec1}
===============

Upper airway diseases compass acute and chronic conditions. In this study, we focus on recurrent upper respiratory tract infections (RURT), allergic rhinitis (AR), nonallergic rhinitis (NAR), and acute and chronic rhinosinusitis (ARS/CRS) with and without nasal polyps. These disorders are extremely common and present in all ages, all ethnic populations, and all countries \[[@B1]\]. Apart from their high socioeconomic burden \[[@B2]\], "comorbidities are common and increase the complexity of the management and costs" \[[@B1]\].

Rhinitis is a symptomatic inflammation of the nasal mucosa including nasal symptoms like rhinorrhea, nasal obstruction, nasal itching, and sneezing \[[@B3]\]. The most common form of noninfectious rhinitis is AR with immunoglobulin E- (IgE-) mediated immune response after allergen exposure \[[@B1]\]. Nonallergic rhinitis shows periodic or perennial symptoms, which are not IgE-dependent such as infectious or vasomotor rhinitis \[[@B4]\]. Infectious rhinitis has either viral, bacterial, or other infectious agents origin \[[@B3]\] and affects millions of people annually \[[@B5]\].

Rhinitis and sinusitis mostly coexist and have been proposed as*rhinosinusitis*\[[@B6]\]. The European Position Paper on Rhinosinusitis and Polyps*EPOS* 2012 \[[@B7]\] defines rhinosinusitis as an inflammation of the nose and paranasal sinuses characterised by two or more symptoms, one of which should be either nasal blockage/obstruction/congestion or nasal discharge. Further, either endoscopic or CT proof is obligatory. Acute and chronic rhinosinusitis are distinguished in length of illness and grade of decay of symptoms. It is characterised by a duration of more than 12 weeks without complete resolution of symptoms and affects approximately 5--15% of the general population \[[@B7]--[@B9]\].

State-of-the-art documents ARIA \[[@B3]\] and EPOS \[[@B7]\] provide evidence-based treatment guidelines where "anti-inflammatory medication represents the first-line treatment" \[[@B10]\]. Along with steroid/pharmacological treatment, EPOS \[[@B7]\] recommends nasal saline irrigation as additional first-line treatment in acute and chronic rhinosinusitis and after sinonasal surgery \[[@B7]\]. Some reviews also state nasal irrigation as adjunctive treatment for allergic rhinitis, acute upper respiratory tract infections, and rhinitis of pregnancy \[[@B11]--[@B13]\]. Data for nasal inhalation is limited; EPOS \[[@B7]\] mentions inhalation treatment only in acute rhinosinusitis without evidence. Other guidelines from the German Society of Otorhinolaryngology have an open suggestion for inhalation in rhinosinusitis for symptomatic relief \[[@B14]\].

The current treatment regimens for CRS and AR are effective in the majority of patients, but there are a number of patients still suffering from symptoms \[[@B10]\]. Especially under chronic conditions with long-term drug consumption like glucocorticosteroids, many patients hesitate to take medicine. A publication by Kaschke points out that 64% of AR patients have steroid phobia \[[@B15]\]. It is observed that more and more patients inquire about nonpharmacological therapy approaches in the treatment of rhinosinusitis \[[@B16]\]. Possible approaches besides the proven saline irrigation could be the use of thermal water irrigations and inhalations.

Concerning medical spending, a study by Bhattacharyya points out that the annual costs for medication to treat CRS with intranasal steroids, nonsedating antihistamines, and antibiotic therapy were \$213, \$227, and \$335 in 2003 \[[@B2]\]. Averaging the annual cost of sinus medications including over-the-counter remedies, nasal steroid sprays, and antibiotics, the calculations of Gliklich and Metson result in \$1220 per patient \[[@B17]\].

In the United States the medical spending for AR almost doubled from \$6.1 billion in 2000 to \$11.2 billion in 2005 \[[@B18]\]. Nasal saline irrigation in AR patients helps to reduce medicine consumption by an average of 2.99% \[[@B19]\]. Thermal water applications present an inexpensive nonpharmacological adjunction as well and could therefore further reduce the medicine consumption and costs.

Thermal water treatment belongs to Balneology. Balneology (lat.*balneum*: bath) is the science of natural curative waters, curative gases, and peloides and their use in the treatment of diseases not only as baths, inhalations, or irrigations but also as drinking cures or mud packs \[[@B20]\]. Thermal inhalations and irrigations are century-old practices and already the Romans appreciated the health-promoting effects of different thermal sources.

According to German regulations, natural curative waters are characterised by a minimum content of 1 g dissolved minerals per liter. The designation "thermal water" requires a temperature of a minimum of 20°C when emerging from the spring \[[@B21]\]. Among the many different types of thermal waters our focus is on sulphurous and radon waters. Sulphurous water and its therapeutical use belong to the oldest forms of balneology. It is said to break disulphide bonds of the mucin and activate breathing and blood circulation and helps to reduce inflammation \[[@B20], [@B22], [@B23]\]. Radon is a radioactive gas which emits alpha rays. Its very low content in thermal sources has biopositive effects which stimulate cellular activity \[[@B24]\].

Several studies show significant results in thermal water treatment with inhalation or irrigation treatment \[[@B25]--[@B29]\]. Up to now no systematic review or meta-analysis on thermal water application in upper airway diseases exists.

2. Materials and Methods {#sec2}
========================

A comprehensive search in the databases of MEDLINE (Medical Literature Analysis and Retrieval System Online), CENTRAL (Cochrane Central Register of Controlled Trials), EMBASE (Excerpta Medica Database), Web of Science, and MedPilot was conducted. In the systematic search the terms "thermal water," "Spa therapy," "thermal water inhalations," and "Spa treatment" were combined with the terms "rhinitis," "rhinosinusitis," "allergic rhinitis," "chronic rhinitis," and "nasal irrigation" with the Boolean operator "and" in all fields. Furthermore, the terms "Radon Spa therapy," "Balneotherapy," "Sulphurous Water," "Bromide Water," "Iodic Water," "Salty Water," and "Radon Water" were linked through "and" with "rhinitis" or "rhinosinusitis." No limitation was made in language, publication date, and duration of the study or the demographic data of patients. Literature published up to and including 27 February 2014 was included.

The inclusion criteria for this meta-analysis were as follows: clinical studies conducted with thermal water for the upper airway diseases, allergic, chronic, or acute rhinosinusitis, at least three or more points on the modified JADAD scale \[[@B30]\], and the presence of the complete statistical data sets consisting of mean deviation, standard deviation, and sample size (if appropriate, calculation using standard error or the upper and lower quartile) at defined follow-up time points.

The following outcome parameters were examined in this study: the mucociliary clearance time (MCT), nasal respiratory flow (Flow), nasal resistance (R), immunoglobulin values A, E, G, and M, and adverse events (AE).

3. Data Collection and Analysis {#sec3}
===============================

The search described above initially resulted in 2113 matches. Duplicates and studies that were either nonclinical or disease-specific not relevant for this analysis were excluded so that the abstracts of 50 remaining studies were examined. Another 15 could be excluded after the perusal of the abstract. 35 studies were investigated in full-text which led to the exclusion of another seven studies due to divergent treatment modalities \[[@B22], [@B31], [@B32]\], mismatching disease patterns \[[@B33], [@B34]\], unavailability \[[@B35]\], or the conduction of the study with animals \[[@B36]\].

The remaining 28 articles were evaluated by two independent reviewers with the modified Jadad Scale by Oremus et al. \[[@B30]\]. It amplifies the original 3-item Jadad Scale \[[@B37]\] consisting of randomization, blinding, and study dropouts by adding inclusion/exclusion criteria, side effects, and statistical methods. Additionally, it features two bonus points for appropriate randomisation method and double-blinding. If this does not apply, these points are deducted. The minimum score is 0 points; the maximum score is 8 points.

We set a minimal score of at least three points to establish a qualitative homogeneity essential for our meta-analysis. Thus another 15 studies were excluded \[[@B38]--[@B52]\] and 13 studies remained for our analysis. Four of those are in Italian and nine in English.

The different thermal waters used in the studies included were pooled concerning their different substances. This resulted in two main groups: sulphurous water with nine studies \[[@B25]--[@B28], [@B53]--[@B57]\] and radon water with two studies \[[@B29], [@B58]\]. Salt-bromine-iodine water \[[@B59]\] and hypermineral chloride sodium water \[[@B60]\] were used once. We also pooled a common thermal water group to compare it to isotonic sodium chloride solution (ISCS) and placebo. [Figure 1](#fig1){ref-type="fig"} shows a flowchart of the literature identification process. Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"} show the included studies in a systemic overview.

3.1. Statistical Methods {#sec3.1}
------------------------

The statistical calculations were performed using the statistic software Comprehensive Meta-Analysis Version 2.2.064 (Biostat, Inc.). The study values for the identified outcome parameters were sorted according to the time of measurement (baseline, 12 days, 2 weeks, 30 days, and 90 days). Studies with the same parameter and different (follow-up) times of measurement, of 12 and 14 days, were combined to one-time measurement (2 weeks). All points of measurements of the different studies were summarised and analysed using the random-effect model. The mean and, respectively, the standard error of the mean are depicted in the figures (Figures [2](#fig2){ref-type="fig"}--[5](#fig5){ref-type="fig"}). In the following analysis we assumed a significance if the *P* value was less than or equal to 5% (*P* ≤ 0.05). For clarification, significant improvements/changes are marked with  \* in Tables [4](#tab4){ref-type="table"}--[7](#tab7){ref-type="table"}. For some identified parameters data were available from one study only and therefore had to be excluded from the meta-analysis but are, for the sake of completeness, included in the figures with an interrupted line.

4. Results {#sec4}
==========

In total, 13 studies published between 1998 and 2013 have been included in this analysis.

All forms of applications were pooled. The specific form of application and the number of patients is depicted in [Table 3](#tab3){ref-type="table"}. An aerosol therapy is categorised under inhalations. Altogether, 430 patients received irrigations and 557 patients inhalations.

4.1. Study Design {#sec4.1}
-----------------

All studies feature a prospective study design. Five studies are randomised, controlled, and double-blind \[[@B25]--[@B28], [@B54]\]; other three studies are randomised and controlled \[[@B56], [@B59], [@B60]\]; one study is controlled and double-blind \[[@B29]\]; one is only double-blind \[[@B55]\]. The remaining studies are not randomised, blinded, or controlled \[[@B53], [@B57], [@B58]\]. ISCS was used for the control groups, drinking water or distilled water for placebo groups. The duration of the studies varies between 12 days and 6 months.

4.2. Selection of Patients {#sec4.2}
--------------------------

A total number of 840 patients aged between 2 and 100 years took part in these studies, 510 of them received an application with thermal water, 285 were treated with ISCS \[[@B25]--[@B28], [@B56], [@B59]\], 20 inhaled drinking water \[[@B29]\], and 25 inhaled distilled water \[[@B54]\].

4.3. Mucociliary Clearance Time {#sec4.3}
-------------------------------

MCT was examined in seven studies with 422 patients in total ([Table 4](#tab4){ref-type="table"}). Thermal water (radon, sulphur, and salt-bromine-iodine) applications showed a significant improvement of MCT compared to baseline at both points of measurement ([Figure 2](#fig2){ref-type="fig"}). The measurement for ISCS compared to baseline showed no significance after two weeks but after 90 days in the followup. Only one study was conducted with placebo which did not show any significance neither did radon water applications (*P* = 0.059). Sulphurous water applications showed significant lower values after two weeks compared to the baseline value (*P* \< 0.01) and are also significant lower after 90 days compared to the baseline values (*P* \< 0.01).

In an internal comparison between the ISCS group and the sulphurous water group we had nonsignificant initial situations (*P* = 0.211), but after 2 weeks and 90 days the outcome differed significantly (*P* \< 0.01). The ISCS and the radon group already differed significantly in baseline values (*P* \< 0.05) and had almost parallel curves.

[Figure 2](#fig2){ref-type="fig"} illustrates all values calculated in the meta-analysis and noted in [Table 4](#tab4){ref-type="table"}.

4.4. Nasal Resistance {#sec4.4}
---------------------

Nasal resistance was measured in six of the included trials with a total number of 347 patients ([Table 5](#tab5){ref-type="table"}). Thermal water treatment was not significant after two weeks but after 30 and 90 days compared to baseline. ISCS treatment showed significance after two weeks and 30 days compared to baseline, but after 90 days there was no significance. This graph ([Figure 3](#fig3){ref-type="fig"}, ISCS graph) showed a very erratic curve due to the very heterogeneous study design and the different points of measurement of the three studies included. Both the treatment with placebo and the treatment with radon water showed significance after two weeks. The treatment with sulphurous water showed significance after 30 (*P* \< 0.01) and 90 days (*P* \< 0.05) but not after two weeks (*P* = 0.118).

4.5. Nasal Flow {#sec4.5}
---------------

The nasal flow was specified in three of the included trials with 117 patients ([Table 6](#tab6){ref-type="table"}). All of these patients received inhalation and aerosol therapy. [Figure 4](#fig4){ref-type="fig"} shows all included studies, using this outcome parameter, the dotted lines for placebo and sulphur indicate single studies. Compared to baseline, the combined thermal water group (*P* \< 0.05), as well as the radon (*P* \< 0.05) and the sulphurous water group (*P* \< 0.01), showed significant improvement after two weeks, whereas drinking water application (*P* = 0.425) showed no improvement or significance.

4.6. Immunoglobulins E, A, G, and M {#sec4.6}
-----------------------------------

Immunoglobulin concentrations in the blood were examined in two of the included trials \[[@B25], [@B26]\] with a total number of 180 patients. Both studies compared sulphurous water treatment to ISCS treatment. Distribution of the number of patients (90 patients per group) was equal in both studies.

4.7. IgE {#sec4.7}
--------

[Figure 5](#fig5){ref-type="fig"} illustrates the meta-analysis outcome for IgE. Both groups started from a comparable initial position. Sulphurous water treatment rose significantly (*P* \< 0.01) at both measurement points 12 and 90 days compared to baseline in contrast to ISCS treatment which was neither significant after 12 days (*P* = 0.442) nor after 90 days (*P* = 0.567).

4.8. IgA, G, and M {#sec4.8}
------------------

No significant differences could be revealed in the analysis of the immunoglobulins A, G, and M, neither beyond the subgroups between ISCS and sulphur nor in the individual groups between the baseline and the maximal treatment duration of 90 days.

4.9. Adverse Events {#sec4.9}
-------------------

All adverse events that occurred during the studies in the entire patient population were extracted and illustrated in forest plots. In total, 19 patients out of 840 treated patients suffered from study related adverse events. All adverse events occurred under the treatment with sulphurous water: 13 patients experienced mild nasal irritation and a sensation of burning after application and five suffered from very limited epistaxis, one from an aggravation of the symptoms, and one from dermatological hypersensitivity. No adverse events are reported for the treatment with another thermal water, ISCS, or placebo.

For sulphurous water, 19 adverse events occurred in a total group of 370 patients. This led to an adverse event rate of 11.9%. The assumed rate of adverse events ranged from 7.8 to 17.6% ([Figure 6](#fig6){ref-type="fig"}).

By pooling all thermal water subgroups we received a total number of 510 treated patients with 19 adverse events. This led to an adverse event rate of 9.8% with an assumed range from 6.6 to 14.4% ([Figure 7](#fig7){ref-type="fig"}).

5. Discussion {#sec5}
=============

This review and its appertaining meta-analysis is the first systematic approach to thermal water treatment in upper respiratory tract diseases. For the identified outcome parameters some significant improvements could be found in the treatment with thermal water irrigation and inhalation.

In order to ensure methodological quality of the included trials, two independent reviewers applied the modified Jadad Scale to every study with a minimal score of 3.

Further this meta-analysis is calculated by the "random effects" model, which takes possible heterogeneity more into consideration than the "fixed effect" model. The confidence intervals are broader and thus capture the true value of the meta-analysis. Where relative overestimation of smaller studies can result in greater inaccuracy, this is a more conservative and cautious estimation. It constitutes a higher risk for bias of the results \[[@B63]\].

In addition, we pooled the clinical pictures of allergic, acute, and chronic rhinosinusitis as well as studies with children, adults, and elderly people. In two studies patients with minimally invasive functional endoscopic sinus surgery (FESS) before treatment were included. This can be assumed as selection bias for this meta-analysis. Furthermore, only published studies were included in this meta-analysis. Thus, publication bias may occur.

Besides irrigation, also inhalation therapy was used in the different studies. Both treatments reduced inflammatory mediators in nasal secretions \[[@B64]\]. Nasal irrigation had a direct physical cleansing effect by flushing out thick mucus, crusts, debris, allergens, and air pollutants \[[@B65]\]. In a review by Hermelingmeier et al. the conclusion drawn is that there is no clear data available naming the most advantageous form of application in nasal saline irrigation \[[@B19]\].

The present meta-analysis shows a significant advantage of mucociliary clearance changes with thermal water in comparison to isotonic saline solution. This leads to a more detailed view of the results of thermal water applications found in this meta-analysis.

The MCT parameter comprises the best set of data in our meta-analysis with seven included studies and 422 patients. Mucociliary clearance is an important defence mechanism for both upper and lower airways and "its impairment\[...\] predisposes to chronic infection of the nose, paranasal sinuses and the respiratory tree" \[[@B66]\]. The average MCT values range below 15 minutes with a test duration of less than 1 hour \[[@B67]\]. In this meta-analysis a significant improvement of the mucociliary clearance could be determined in thermal water applications. Hereby, the transport time could be reduced from 19.67 minutes initially to 12.98 minutes after two weeks and to 11.34 minutes after 90 days. Especially the application of sulphurous water showed a high significance (*P* \< 0.001) after the two-week treatment period. At the same time the treatment with radon thermal water (*P* = 0.059) only just lacked a significant improvement (*P* = 0.059).

The literature available for these two subgroups was 5 : 2 with only 60 patients in the radon group which might have had an influence on the significance. In contrast to the thermal water group, the ISCS group only showed significance after 90 days of treatment. In turn the literature available was quite strong with 4 studies and a total of 205 patients.

Based on Marullo\'s study only it was not possible to conduct a meta-analysis and draw a valid conclusion on the use of placebo \[[@B29]\]. The meta-analysis of the mucociliary clearance time showed a significant benefit especially of the pooled thermal water treatment and sulphurous water over ISCS.

The "nasal resistance is the resistance offered by the nasal cavity to inspired air" \[[@B68]\] and it is measured in Pascal (Pa). All studies used for this analysis already resulted in significant changes after two weeks of treatment with radon thermal water. ISCS differed significantly after two weeks and after 30 days of treatment. The meta-analysis revealed significant variations in the three pooled ISCS studies. Especially the study of Salami et al. displayed a high deviation from the baseline of 13.1 Pa, which was reduced to 1.28 Pa after two weeks and remained rather high after 90 days of treatment with 1.12 Pa.

Opposed to these findings were those of the two other studies of this pool \[[@B27], [@B28]\], which began with much lower baseline values of 0.14 and 0.17 Pa and had different followups. Therefore these led to an unsteady curve and limited the possibility of a serious interpretation of the healing process. Nevertheless, each of these three studies showed a reduction of the nasal resistance.

The treatment with sulphurous water showed good results throughout the whole treatment period of 90 days. The results were even better after 30 and 90 days than at the beginning, which allows for the assumption that a more permanent improvement is gained here.

Based on this meta-analysis we can assume that radon water application shows significant improvement in nasal flow. The data is quite limited with the results of only one study for placebo and one for sulphurous treatment, so that we cannot compare it to the pooled results.

The use of radon thermal water as well as the entire thermal water subgroup showed a significant improvement in the nasal flow after two weeks of treatment.

In our meta-analysis of IgE, sulphurous water treatment was highly significant after 12 and 90 days. ISCS treatment showed no significance. The present IgE results were measured in patients with chronic inflammatory conditions, where eosinophil cells in the mucus are increased \[[@B69]\]. Reduction of eosinophil cells after thermal water treatment was also reported in Passali et al. \[[@B58]\] and significantly decreased in Staffieri and Abramo \[[@B55]\]. Hypereosinophilia is related to high levels of serum concentrations of IgE \[[@B26], [@B70]\]. The IgE concentration which decreased significantly after the application with sulphurous water confirmed beneficial effects on chronic inflammatory disorders. Sulphurous water helps to clean the nasal mucosa from irritations and reduces immune responses at a local level \[[@B25], [@B71]\]. These results support the assumption that sulphurous water has an anti-inflammatory effect.

IgA, IgG, and IgM values in the blood did not increase significantly neither with sulphurous water nor with ISCS. Unfortunately the literature available on the secretory IgA, which is secreted across the mucosa and plays a significant role in specific immune defence by preventing or blocking the adhesion of bacteria and defending the mucous membranes from common infection \[[@B72], [@B73]\], was not sufficient for a statistical analysis. Similarly, comparable studies investigating the IgM and IgG in the mucosa were missing.

Generally speaking, thermal water application is a safe treatment. Adverse events occurred in 19 out of 510 thermal water treatments and mainly consisted of mild nasal irritation, a sensation of local burning after application, and very limited epistaxis. All of these adverse events occurred under the treatment with sulphurous water. Neither for radon water, ISCS, nor placebo treatment adverse events were reported. It should be noted that both the studies by Staffieri et al. \[[@B56]\] and Ottaviano et al. \[[@B28]\] were conducted in a postoperative setting, which makes the occurrence of such adverse events more likely. Further, the study by De Luca et al. \[[@B53]\] was conducted with elderly people between 72 and 100 years.

6. Conclusion {#sec6}
=============

Nasal application of thermal water results in a significant improvement of MCT, nasal flow, nasal resistance, and IgE concentration. The systematic review and the meta-analysis demonstrate an advantage of thermal water treatment over isotonic saline solution and placebo. Even though this aspect needs to be investigated further with randomised controlled trials in bigger cohorts and longer follow-up periods, it was shown that the application with thermal water can serve as additional nonpharmacological alternative.
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###### 

Included studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                   Year   Study design                                              Thermal water/control                                                             Application                                               Adverse events   MCT   Flow   Resistance   IgA   IgE   IgG   IgM
  ---------------------------------------- ------ --------------------------------------------------------- --------------------------------------------------------------------------------- --------------------------------------------------------- ---------------- ----- ------ ------------ ----- ----- ----- -----
  De Luca et al. \[[@B53]\]                2006   Prospective, nonrandomized, noncontrolled                 Sulphur/---                                                                       Inhalation 1x daily 10 min for 12 days                    X                X                                            

                                                                                                                                                                                                                                                                                                                     

  Marullo and Abramo \[[@B29]\]            2000   Prospective, nonrandomized, controlled, double-blind      Radon/Tap water                                                                   Inhalation 10 min,\                                       X                X     X      X                               
                                                                                                                                                                                              Aerosol 10 min, 1x daily for 12 days                                                                                   

                                                                                                                                                                                                                                                                                                                     

  Miraglia del Giudice et al. \[[@B60]\]   2011   Prospective, randomized, controlled                       Hypermineral chloride sodium water/ISCS                                           Aerosol 15 days a month for 3 months/\                    X                                                             
                                                                                                                                                                                              ISCS daily for 3 months                                                                                                

                                                                                                                                                                                                                                                                                                                     

  Ottaviano et al. \[[@B27]\]              2012   Prospective, randomized, controlled, double-blind         Sulphur-Arsenic-Ferrous water diluted to 10% solution with distilled water/ISCS   Irrigation 1x daily 20 mL for 1 month                     X                             X                               

                                                                                                                                                                                                                                                                                                                     

  Ottaviano et al. \[[@B28]\]              2011   Prospective, randomized, controlled, double-blind         Sulphur-Salt-Bromine-Iodine/ISCS                                                  Irrigation 4x daily 5 mL for 1 month                      X                             X                               

                                                                                                                                                                                                                                                                                                                     

  Passali et al. \[[@B58]\]                2013   Prospective, nonrandomized, noncontrolled                 Radon/---                                                                         Inhalation, Aerosol, each 10 min 1x daily for 14 days     X                X     X      X                               

                                                                                                                                                                                                                                                                                                                     

  Passali et al. \[[@B59]\]                2008   Prospective, randomized, controlled                       Salt-Bromine-Iodine/ISCS                                                          Inhalation 10 min,\                                       X                X                                            
                                                                                                                                                                                              Aerosol 10 min,\                                                                                                       
                                                                                                                                                                                              Irrigation 5 min 1x daily for 14 days                                                                                  

                                                                                                                                                                                                                                                                                                                     

  Passariello et al. \[[@B57]\]            2012   Prospective, nonrandomized, noncontrolled                 Sulphate-Sodium-Chloride/---                                                      Aerosol 15 min 1x daily for 15 days                       X                                                             

                                                                                                                                                                                                                                                                                                                     

  Salami et al. \[[@B26]\]                 2010   Prospective, randomized, controlled, double-blind         Sulphur/ISCS                                                                      Inhalation, 10 min\                                       X                X            X            X     X     X     X
                                                                                                                                                                                              Irrigation 6 min 1x daily for 12 days                                                                                  

                                                                                                                                                                                                                                                                                                                     

  Salami et al. \[[@B25]\]                 2008   Prospective, randomized, controlled, double-blind         Sulphur/ISCS                                                                      Inhalation 10 min 1x daily for 12 days                    X                X                         X     X     X     X

                                                                                                                                                                                                                                                                                                                     

  Staffieri et al. \[[@B56]\]              2008   Prospective, randomized, controlled                       Sulphur-Arsenic-Ferrous water diluted to 10% solution with distilled water/ISCS   Irrigation 4x daily 20 mL for 6 months                    X                                                             

                                                                                                                                                                                                                                                                                                                     

  Staffieri and Abramo \[[@B55]\]          2007   Prospective, nonrandomized, noncontrolled, double-blind   Sulphur-Arsenic-Ferrous water/---                                                 Inhalation,\                                              X                X     X      X                               
                                                                                                                                                                                              Aerosol\                                                                                                               
                                                                                                                                                                                              each 10 min, 1x daily for 12 days                                                                                      

                                                                                                                                                                                                                                                                                                                     

  Staffieri et al. \[[@B54]\]              1998   Prospective, randomized, controlled, double-blind         Sulphur-Salt-Bromine-Iodine/distilled water                                       Inhalation, 10 min, Aerosol 10 min 1x daily for 12 days   X                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Systematic presentation of the studies included.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                   Year   Jadad score   Number of patients thermal water/control   Age span/average age    Duration of treatment          Measurement time points      Inclusion criteria                                                                                                                                                                    Exclusion criteria
  ---------------------------------------- ------ ------------- ------------------------------------------ ----------------------- ------------------------------ ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  De Luca et al. \[[@B53]\]                2006   3             40/---                                     74--100/86,5            12 days                        Baseline\                    \(i\) Presence of chronic rhinitis or chronic rhinosinusitis\                                                                                                                         \(i\) Acute pathologies in ENT region\
                                                                                                                                                                  Follow-Up: Day 12            (ii) Allergic or vasomotor nasal hyperactivity\                                                                                                                                       (ii) Steroids, mucolytics, antihistamine, NSAIDs, vasoconstrictive drugs or antibiotics in the last 30 days\
                                                                                                                                                                                               (iii) Chronic laryngitis\                                                                                                                                                             (iii) Autoimmune disease\
                                                                                                                                                                                               (iv) Chronic pharyngitis                                                                                                                                                              (iv) Patients with malignant neoplasms, surgical intervention, and/or radio chemotherapy

                                                                                                                                                                                                                                                                                                                                                                                     

  Marullo and Abramo \[[@B29]\]            2000   3             27/20                                      15--81/52.4             12 days                        Baseline\                    \(i\) At least 3 confirmed episodes of sinonasal infection in the previous 12 months\                                                                                                 \(i\) Vasoconstrictive drugs, local and systemic steroids, NSAIDs, antihistamine, and mucolytics in the last 2 months\
                                                                                                                                                                  Follow-Up: Day 12            (ii) Evidence of chronic sinonasal inflammation at objective otorhinolaryngologic evaluation                                                                                          (ii) Patients who for various reasons were not able to ensure the conclusion of the study\
                                                                                                                                                                                                                                                                                                                                                                                     (iii) Patients who present anterior rhinoscopy

                                                                                                                                                                                                                                                                                                                                                                                     

  Miraglia del Giudice et al. \[[@B60]\]   2011   5             20/20                                      6--14/                  15 days a month for 3 months   Baseline\                    \(i\) Age from 6 to 14\                                                                                                                                                               \(i\) Antihistamines, intranasal, bronchial, or systemic corticosteroids, cromolyn sodium, and leukotriene modifiers in the previous 6 weeks\
                                                                                                                                                                  Follow-Up: Week 12, 14       (ii) History of seasonal moderate to severe allergic rhinitis for at least 2 years\                                                                                                   (ii) sinus and/or upper or lower respiratory tract infection, persistent asthma, nasal surgery within the last year, respiratory tract abnormalities, and systemic diseases
                                                                                                                                                                                               (iii) Positive skin prick test to *Parietaria* pollen\                                                                                                                                
                                                                                                                                                                                               (iv) History of mild intermittent asthma                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                     

  Ottaviano et al. \[[@B27]\]              2012   5             35/35                                      18--65/\                12 weeks                       Baseline\                    \(i\) Age from 18 to 65\                                                                                                                                                              Autoimmune diseases, cystic fibrosis, and diabetes
                                                                                                           not specified                                          Follow-Up: Day 30, 90        (ii) Nonallergic chronic rhinitis\                                                                                                                                                    
                                                                                                                                                                                               (iii) Cigarette smoking habit for at least 5 years                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                     

  Ottaviano et al. \[[@B28]\]              2011   8             40/40                                      18--65/\                1 month                        Baseline\                    \(i\) Age from 18 to 65\                                                                                                                                                              Autoimmune diseases, cystic fibrosis, and diabetes
                                                                                                           not specified                                          Follow-Up: Day 30            (ii) Nonallergic chronic rhinosinusitis                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                     

  Passali et al. \[[@B58]\]                2013   3             33/---                                     12 years and older/ \   14 days                        Baseline\                    \(i\) Nasal obstruction evaluated by a 10-point Visual Analog Scale (1: nasal airways completely free; 10: nasal airway completely blocked) higher than 7 in the previous 2 months\   \(i\) Acute viral rhinitis\
                                                                                                           not specified                                          Follow-Up: Day 14            (ii) Chronic rhinosinusitis, persistent allergic rhinitis, vasomotor rhinitis with inferior turbinate hypertrophy                                                                     (ii) Obstructive polyposis\
                                                                                                                                                                                                                                                                                                                                                                                     (iii) Nasal steroid, vasoconstrictive drug therapies or systemic NSAIDs, oral steroids and mucolytic treatment in the previous 2 months

                                                                                                                                                                                                                                                                                                                                                                                     

  Passali et al. \[[@B59]\]                2008   3             60/60                                      15--65/not specified    14 days                        Baseline\                    Chronic rhinosinusitis with/or nasal polyposis of I second degree of the Lund-Mackay-Classification \[[@B62]\]                                                                        Not specified
                                                                                                                                                                  Follow-Up: Day 14                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                     

  Passariello et al. \[[@B57]\]            2012   3             60/---                                     2--12/3.4 ± 1           15 days                        Baseline\                    \(i\) Age from 2 to12\                                                                                                                                                                \(i\) Steroids, nonsteroidal anti-inflammatory drugs, antihistamines, and vasoconstrictors in the previous 4 weeks\
                                                                                                                                                                  Follow-Up: Day 15            (ii) CRS\                                                                                                                                                                             (ii) Primary diagnosis of obstructive sleep apnea syndrome caused by tonsillar hyperplasia\
                                                                                                                                                                                               (iii) One or more of the following sinonasal symptoms: nasal discharge, congestion, obstruction, postnasal drip, daytime cough, and foul breath\                                      (iii) Chronic diseases, immunodeficiency, and neurological impairment\
                                                                                                                                                                                               (iv) Failed courses of antibiotics, saline irrigation, nasal steroids, or antihistamine\                                                                                              (iv) Varicose veins of the nasal septum, and suspect ciliary abnormalities\
                                                                                                                                                                                               (v) Persistent symptoms for ≥1 month                                                                                                                                                  (v) Previous sinonasal surgery\
                                                                                                                                                                                                                                                                                                                                                                                     (vi) Malformation of the upper airway\
                                                                                                                                                                                                                                                                                                                                                                                     sinonasal osteogenesis, tumors, and obstructive lesions\
                                                                                                                                                                                                                                                                                                                                                                                     (vii) History of facial trauma that distorted the sinus anatomy

                                                                                                                                                                                                                                                                                                                                                                                     

  Salami et al. \[[@B26]\]                 2010   5             40/40                                      26--58/46.4             12 days                        Baseline\                    CRS without polyps                                                                                                                                                                    \(i\) Immunostimulant or immunosuppressive agents in the previous 6 months\
                                                                                                                                                                  Follow-Up: Day 12, 90                                                                                                                                                                                              (ii) Genetic and congenital condition: cystic fibrosis and primary ciliary dyskinesia\
                                                                                                                                                                                                                                                                                                                                                                                     (iii) Nasal polys\
                                                                                                                                                                                                                                                                                                                                                                                     (iv) Positive allergy testing\
                                                                                                                                                                                                                                                                                                                                                                                     (v) Anatomic abnormalities (severe septal deviation among others)\
                                                                                                                                                                                                                                                                                                                                                                                     (vi) Acquired mucociliary dysfunction\
                                                                                                                                                                                                                                                                                                                                                                                     (vii) Neoplasms\
                                                                                                                                                                                                                                                                                                                                                                                     (viii) Acute contemporary bacterial and/or viral rhinosinusitis, middle ear, and respiratory tract\
                                                                                                                                                                                                                                                                                                                                                                                     (ix) Bronchopulmonary disease\
                                                                                                                                                                                                                                                                                                                                                                                     (x) Nasal trauma\
                                                                                                                                                                                                                                                                                                                                                                                     (xi) Smoker\
                                                                                                                                                                                                                                                                                                                                                                                     (xii) Previous nasal and sinus surgery

                                                                                                                                                                                                                                                                                                                                                                                     

  Salami et al. \[[@B25]\]                 2008   7             50/50                                      6--14/9                 12 days                        Baseline\                    At least 3 acute episodes of upper respiratory tract infections in the last year                                                                                                      \(i\) Immunostimulant or immunosuppressive agents in the previous 6 months\
                                                                                                                                                                  Follow-Up: Day 12, 90                                                                                                                                                                                              (ii) Previous adenoidectomy and/or tonsillectomy\
                                                                                                                                                                                                                                                                                                                                                                                     (iii) Anatomic anomalies\
                                                                                                                                                                                                                                                                                                                                                                                     (iv) Other acute infections\
                                                                                                                                                                                                                                                                                                                                                                                     (v) Allergic rhinitis\
                                                                                                                                                                                                                                                                                                                                                                                     (vi) Congenital immunodeficiency\'s  \
                                                                                                                                                                                                                                                                                                                                                                                     (vii) Pulmonary disease

                                                                                                                                                                                                                                                                                                                                                                                     

  Staffieri et al. \[[@B56]\]              2008   5             40/40                                      18--65/not specified    6 months                       Baseline\                    \(i\) Age from 18 to 65\                                                                                                                                                              \(i\) Autoimmune disease\
                                                                                                                                                                  Follow-Up: Day 30, 90, 180   (ii) CRS not responding to medical treatment\                                                                                                                                         (ii) Cystic fibrosis\
                                                                                                                                                                                               (iii) No contraindications to general anaesthesia and FESS                                                                                                                            (iii) Diabetes\
                                                                                                                                                                                                                                                                                                                                                                                     (iv) Sinonasal inverted papilloma or sinonasal malignancy

                                                                                                                                                                                                                                                                                                                                                                                     

  Staffieri and Abramo \[[@B55]\]          2007   4             37/---                                     40/not specified        12 days                        Baseline\                    \(i\) At least 3 confirmed episodes of sinonasal infection in the previous 12 months\                                                                                                 Nasal steroid, vasoconstrictive drug therapies or systemic NSAIDs, and steroid or mucolytic treatments in the previous 2 months
                                                                                                                                                                  Follow-Up: Day 12            (ii) Evidence of chronic sinonasal inflammation at otorhinolaryngologic endoscopic evaluation                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                     

  Staffieri et al. \[[@B54]\]              1998   3             25/25                                      18--83/50.5             12 days                        Baseline\                    Chronic rhinopharyngotubaric inflammation                                                                                                                                             Not specified
                                                                                                                                                                  Follow-Up: Day 12                                                                                                                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Type of application.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Application          Inhalation                   Inhalation + aerosol               Irrigation                     Inhalation + irrigation    Inhalation + aerosol + irrigation   Aerosol
  -------------------- ---------------------------- ---------------------------------- ------------------------------ -------------------------- ----------------------------------- -----------------------------------------
  Number of patients   140                          117                                230                            80                         120                                 100

  Study                De Luca et al. \[[@B53]\]\   Marullo and Abramo \[[@B29]\]\     Ottaviano et al. \[[@B27]\]\   Salami et al. \[[@B26]\]   Passali et al. \[[@B59]\]           Miraglia del Giudice et al. \[[@B60]\]\
                       Salami et al. \[[@B25]\]     Passali et al. \[[@B58]\]\         Ottaviano et al. \[[@B28]\]\                                                                  Passariello et al. \[[@B57]\]
                                                    Staffieri and Abramo \[[@B55]\]\   Staffieri et al. \[[@B56]\]                                                                   
                                                    Staffieri et al. \[[@B54]\]                                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Results of MCT.

                                                          Patients   MCTt          CI 95%             *P* value
  ------------------------------------------------------- ---------- ------------- ------------------ -----------
  Thermal water (sulphur + salt-bromine-iodine + radon)                                                
   Baseline                                               265        19.67020883   \[17.40; 21.94\]    
   2 weeks                                                265        12.98258754   \[11.34; 14.63\]   \<0.01\*
   90 days                                                90         11.34482778   \[10.91; 11.78\]   \<0.01\*
  ISCS                                                                                                 
   Baseline                                               137        21.81138859   \[18.19; 25.05\]    
   2 weeks                                                137        18.54655442   \[17.09; 20.01\]   0.107
   90 days                                                90         17.60438587   \[17.17; 18.04\]   \<0.05\*
  Placebo                                                                                              
   Baseline                                               20         19.8          \[17.78; 21.82\]    
   2 weeks                                                20         18.5          \[15.65; 21.35\]   0.465
  Radon                                                                                                
   Baseline                                               60         15.84974132   \[11.85; 19.85\]    
   2 weeks                                                60         11.95305164   \[11.33; 12.58\]   0.059
  Sulphur                                                                                              
   Baseline                                               205        19.43087224   \[18.89; 19.97\]    
   2 weeks                                                205        12.57267757   \[10.30; 14.85\]   \<0.01\*
   90 days                                                90         11.34482778   \[10.91; 11.78\]   \<0.01\*

\*Significant in comparison to baseline (*P* \< 0.05).

###### 

Results of nasal resistance.

                             Patients   NasRes        CI 95%            *P* value
  -------------------------- ---------- ------------- ----------------- -----------
  Thermal (sulphur +radon)                                               
   Baseline                  212        0,442260114   \[0.26; 0.62\]     
   2 weeks                   137        0.257467503   \[0.22; 0.30\]    0.051
   30 days                   66         0.113901251   \[0.05; 0.18\]    \<0.01\*
   90 days                   64         0.159927083   \[0.003; 0.32\]   \<0.05\*
  ISCS                                                                   
   Baseline                  115        0.516633      \[0.13; 0.90\]     
   2 weeks                   40         1.28          \[1.16; 1.40\]    \<0.01
   30 days                   62         0.124408602   \[0.10; 0.15\]    \<0.05
   90 days                   68         0.617283393   \[−0.36; 1.60\]   0.851
  Placebo                                                                
   Baseline                  20         0.23          \[0.19; 0.27\]     
   2 weeks                   20         0.19          \[0.17; 0.21\]    \<0.05\*
  Radon                                                                  
   Baseline                  60         0.364606147   \[0.33; 0.40\]     
   2 weeks                   60         0.240700629   \[0.15; 0.33\]    \<0.05\*
  Sulphur                                                                
   Baseline                  152        0.495021367   \[0.22; 0.77\]     
   2 weeks                   77         0.272182942   \[0.26; 0.29\]    0.118
   30 days                   66         0.113901251   \[0.05; 0.18\]    \<0.01\*
   90 days                   64         0.159927083   \[0.003; 0.32\]   \<0.05\*

\*Significant in comparison to baseline (*P* \< 0.05).

###### 

Results of nasal flow.

                              Patients   NasFlow   CI 95%               *P* value
  --------------------------- ---------- --------- -------------------- -----------
  Thermal (sulphur + radon)                                              
   Baseline                   97         604.1     \[513.68; 694.45\]    
   12--14 days                97         721.5     \[697.18; 745.84)    \<0.05\*
  Placebo                                                                
   Baseline                   20         714.3     \[664.13; 764.47\]    
   12--14 days                20         687.5     \[644.79; 730.21\]   0.425
  Radon                                                                  
   Baseline                   60         633.4     \[540.95; 725.90\]    
   12--14 days                60         738.8     \[703.64; 773.89\]   \<0.05\*
  Sulphur                                                                
   Baseline                   37         558.4     \[526.53; 590.27\]    
   12--14 days                37         705.6     \[671.86; 739.34\]   \<0.01\*

\*Significant in comparison to baseline (*P* \< 0.05).

###### 

Results of IgE.

              Patients   IgE      CI 95%              *P* value
  ----------- ---------- -------- ------------------- -----------
  Sulphur                                              
   Baseline   90         105.11   \[98.53; 111.69\]    
   12 days    90         75.65    \[70.13; 81.18\]    \<0.01\*
   90 days    90         74.79    \[69.38; 80.19\]    \<0.01\*
  ISCS                                                 
   Baseline   90         101.69   \[94.03; 109.35\]    
   12 days    90         97.10    \[88.22; 105.98\]   0.442
   90 days    90         98.30    \[89.60; 107.00\]   0.567

\*Significant in comparison to baseline (*P* \< 0.05).

[^1]: Academic Editor: Desiderio Passali
